Suppr超能文献

间变性淋巴瘤激酶阴性间变性大细胞淋巴瘤中假定致病微小RNA及其下游靶点的鉴定

Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.

作者信息

Mehrotra Meenakshi, Medeiros L Jeffrey, Luthra Rajyalakshmi, Sargent Rachel L, Yao Hui, Barkoh Bedia A, Singh Rajesh, Patel Keyur P

机构信息

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030.

出版信息

Hum Pathol. 2014 Oct;45(10):1995-2005. doi: 10.1016/j.humpath.2014.06.012. Epub 2014 Jun 30.

Abstract

Anaplastic large cell lymphomas (ALCL) are tumors of T/null-cell lineage characterized by uniform CD30 expression. The 2008 World Health Organization classification subdivided ALCLs into 2 groups: anaplastic lymphoma kinase (ALK)-positive (established entity) and ALK-negative (proposed new entity) ALCL. The genetic basis for the pathogenesis of newly categorized ALK- ALCL is poorly understood. In this study, we used microRNA microarray analysis to identify differentially expressed microRNAs in ALK+ and ALK- ALCL. ALK- ALCL showed significantly higher expression of miR-155 (0.888 ± 0.228) compared with ALK+ ALCL (0.0565 ± 0.009) on microarray and by quantitative real-time polymerase chain reaction in ALK- ALCL compared with ALK+ ALCL (P < .05) with a strong correlation between the 2 platforms (R = 0.9, P < .0003). A novel in situ hybridization method allows direct visualization of expression patterns and relative quantitation of miR-155 (mean score, 2.3 versus 1.3; P = .01) for the first time in tissue sections of ALCL. Among computationally predicted targets of miR-155, we identified ZNF652 (r = -0.57, P = .05), BACH1 (r = 0.88, P = .02), RBAK (r = 0.81, P = .05), TRIM32 (r = 0.92, P = .01), E2F2 (r = 0.81, P = .05), and TP53INP1 (r = -0.31, P = .03) as genes whose expression by quantitative real-time polymerase chain reaction correlated significantly with the level of miR-155 in ALCL tumor tissue.

摘要

间变性大细胞淋巴瘤(ALCL)是T/null细胞系肿瘤,其特征为CD30表达一致。2008年世界卫生组织分类将ALCL分为两组:间变性淋巴瘤激酶(ALK)阳性(已确定的实体)和ALK阴性(新提出的实体)ALCL。新分类的ALK-ALCL发病机制的遗传基础了解甚少。在本研究中,我们使用微小RNA微阵列分析来鉴定ALK+和ALK-ALCL中差异表达的微小RNA。在微阵列上以及通过定量实时聚合酶链反应,ALK-ALCL中miR-155的表达(0.888±0.228)显著高于ALK+ALCL(0.0565±0.009),在ALK-ALCL与ALK+ALCL之间比较差异有统计学意义(P<0.05),且两个平台之间有很强的相关性(R = 0.9,P<0.0003)。一种新的原位杂交方法首次能够在ALCL组织切片中直接观察miR-155的表达模式并进行相对定量(平均得分,2.3对1.3;P = 0.01)。在miR-155的计算预测靶标中,我们鉴定出锌指蛋白652(ZNF652,r = -0.57,P = 0.05)、巴赫1(BACH1,r = 0.88,P = 0.02)、RBAK(r = 0.81,P = 0.05)、TRIM32(r = 0.92,P = 0.01)、E2F2(r = 0.81,P = 0.05)和TP53诱导蛋白1(TP53INP1,r = -0.31,P = 0.03)等基因,其通过定量实时聚合酶链反应检测的表达与ALCL肿瘤组织中miR-155的水平显著相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验